BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Consensus Recommendation of "Buy" from Analysts

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) have earned an average rating of "Buy" from the five ratings firms that are covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $26.20.

A number of equities research analysts have recently weighed in on the company. Northland Securities boosted their price target on BioLife Solutions from $26.00 to $28.00 and gave the stock an "outperform" rating in a research note on Friday, August 9th. Benchmark upgraded shares of BioLife Solutions from a "neutral" rating to a "buy" rating and set a $25.00 price target on the stock in a research note on Monday, May 13th. Craig Hallum lifted their price objective on shares of BioLife Solutions from $23.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, August 12th. StockNews.com raised shares of BioLife Solutions to a "sell" rating in a report on Friday, May 10th. Finally, TD Cowen raised their target price on BioLife Solutions from $20.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, July 17th.

BioLife Solutions Stock Up 0.6 %

Shares of BioLife Solutions stock traded up $0.15 during trading on Wednesday, reaching $25.72. The company's stock had a trading volume of 338,447 shares, compared to its average volume of 393,603. BioLife Solutions has a 1-year low of $8.92 and a 1-year high of $26.73. The company has a 50-day simple moving average of $22.19 and a two-hundred day simple moving average of $19.82. The company has a quick ratio of 1.77, a current ratio of 2.89 and a debt-to-equity ratio of 0.05. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -18.01 and a beta of 1.85.

Insider Activity

In related news, CMO Todd Berard sold 10,000 shares of BioLife Solutions stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $20.18, for a total transaction of $201,800.00. Following the completion of the transaction, the chief marketing officer now directly owns 108,894 shares in the company, valued at $2,197,480.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CMO Todd Berard sold 10,000 shares of the business's stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $20.18, for a total value of $201,800.00. Following the completion of the sale, the chief marketing officer now directly owns 108,894 shares in the company, valued at $2,197,480.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sarah Aebersold sold 3,000 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $21.03, for a total transaction of $63,090.00. Following the transaction, the insider now directly owns 61,683 shares in the company, valued at $1,297,193.49. The disclosure for this sale can be found here. Insiders sold a total of 14,844 shares of company stock valued at $305,052 in the last quarter. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BioLife Solutions

A number of large investors have recently modified their holdings of the business. Nisa Investment Advisors LLC grew its stake in BioLife Solutions by 167.2% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 1,020 shares in the last quarter. 1620 Investment Advisors Inc. acquired a new stake in shares of BioLife Solutions in the second quarter valued at approximately $35,000. Isthmus Partners LLC grew its holdings in BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 42,265 shares in the last quarter. GAMMA Investing LLC acquired a new stake in BioLife Solutions during the fourth quarter worth about $41,000. Finally, Register Financial Advisors LLC purchased a new stake in shares of BioLife Solutions during the 1st quarter valued at approximately $96,000. Hedge funds and other institutional investors own 93.24% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.